Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma

The First Crystal Structure of the UP1 Domain of hnRNP A1 Bound to RNA Reveals a New Look for an Old RNA Binding Protein

(2015) Christopher E. Morgan et al.   JOURNAL OF MOLECULAR BIOLOGY

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress

(2015) Y Shi et al.   ONCOGENE

Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-cancer Effects in PC-3 Cells

(2014) Chia-Chen Ko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Where is mTOR and what is it doing there?

(2014) Charles Betz et al.   JOURNAL OF CELL BIOLOGY

EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer

(2013) Ivan Babic et al.   Cell Metabolism

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

(2013) B. Gini et al.   CLINICAL CANCER RESEARCH

hnRNP A1: The Swiss Army Knife of Gene Expression

(2013) Jacques Jean-Philippe et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

(2013) Akio Iwanami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

A unifying model for mTORC1-mediated regulation of mRNA translation

(2012) Carson C. Thoreen et al.   NATURE

So you want to know if your message has an IRES?

(2012) Sunnie R. Thompson   Wiley Interdisciplinary Reviews-RNA

Glioblastoma: From Molecular Pathology to Targeted Treatment

(2011) Timothy F. Cloughesy et al.   Annual Review of Pathology-Mechanisms of Disease

Phosphomimetic Substitution of Heterogeneous Nuclear Ribonucleoprotein A1 at Serine 199 Abolishes AKT-dependent Internal Ribosome Entry Site-transacting Factor (ITAF) Function via Effects on Strand Annealing and Results in Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitor Sensitivity

(2011) Jheralyn Martin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma

(2011) C. Cloninger et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis

(2010) Gracjan Michlewski et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

(2009) Oleg Trott et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Heterogeneous Nuclear Ribonucleoprotein A1 Regulates Cyclin D1 and c-mycInternal Ribosome Entry Site Function through Akt Signaling

(2008) Oak D. Jo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE